查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1613337

Devic 症候群治疗市场：按治疗方法、分销管道和最终用户划分 - 全球预测 2025-2030

Devic's Syndrome Treatment Market by Treatment (Corticosteroids, Immunosuppressants, Plasma Exchange (Plasmapheresis)), Distribution Channel (Clinics, Hospitals, Online Pharmacies), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

Devic症候群治疗市场2023年估值为2.1053亿美元，预计到2024年将达到2.2027亿美元，复合年增长率为4.68%，到2030年将达到2.9003亿美元。

Devik 综合征，也称为视神经脊髓炎频谱障碍 (NMOSD)，是一种以视神经和脊髓发炎和去髓鞘化为特征的自体免疫疾病。由于认识的提高、患病率的上升以及允许早期诊断的医疗技术的进步，治疗市场正在扩大。治疗的需要源于该疾病的慢性和復发性，如果不治疗可能导致严重残疾。治疗方法包括血浆置换、免疫抑制疗法和单株抗体（例如Eculizumab），针对该疾病的潜在致病机制。最终用途细分市场包括医院、专科诊所和研究机构，其中具有急症救治综合能力的医院占比较大。

主要市场统计
基准年[2023] 21053万美元
预计年份 [2024] 22027万美元
预测年份 [2030] 29003万美元
复合年增长率（%） 4.68%

市场驱动因素是患者人数的增加和医疗保健支出的增加。合作研究倡议的增加将进一步促进创新，生物技术将为更有效的治疗选择铺平道路。然而，市场面临着治疗成本高、核准的治疗方法数量少以及阻碍开发平臺的监管障碍等挑战。潜在的商机在于策略伙伴关係关係、个人化医疗投资以及探索意识和诊断率较低的新兴市场的未开发潜力。

然而，发展中地区对 NMOSD 的认识较低以及临床试验的复杂性仍然是主要障碍。用于早期检测、提高治疗效果和患者治疗结果的生物标记开发是业务成长的有希望的创新领域。从市场竞争格局来看，各大药厂的优势主要在于强大的研发能力与策略联盟。为了利用这些机会，公司应专注于促进整个医疗保健生态系统的合作，优化供应链，并透过负担能力计画改善病患的就医机会。

市场动态：揭示快速发展的 Devic 综合征治疗市场的关键市场洞察

供给和需求的动态交互作用正在改变德维克综合症治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 德维克综合症在全球呈上升趋势
    • 意识提升的努力和倡导团体的出现
    • 有利的监管核准和政府倡议，确保获得德维克综合征治疗
  • 市场限制因素
    • Devic 症候群是一种复杂的疾病，目前尚无确定的治疗方法。
  • 市场机会
    • 持续努力提高Devic症候群治疗方案的有效性和安全性
    • 患者对个人化和特异性治疗策略的偏好
  • 市场挑战
    • Devic 症候群治疗方案可能产生的副作用

波特五力：驾驭 Devic 症候群治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解对 Devic 症候群治疗市场的外部影响

外部宏观环境因素在塑造德维克综合症治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解 Devic 症候群治疗市场的竞争状况

对德维克综合症治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 Devic 症候群治疗市场供应商的绩效评估

FPNV 定位矩阵是评估 Devic 症候群治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了 Devic 综合征治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对德维克综合症治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 德维克症候群的发生率在世界各地不断增加
      • 提高对神经系统疾病认识的努力和支持团体的出现
      • 有利的监管核准和政府倡议，确保获得 Devic 综合征的治疗
    • 抑制因素
      • 疾病的复杂性和治疗方法无法解决德维克综合征
    • 机会
      • 持续努力提高Devic症候群治疗方案的有效性和安全性
      • 患者更喜欢个人化、针对性的治疗策略
    • 任务
      • 用于治疗德维奇症候群的药物可能产生的副作用
  • 市场区隔分析
    • 治疗方法：皮质类固醇用于治疗德维奇综合征，因为它们可以有效地快速抑制发炎。
    • 最终使用者：为成年患者制定全面的 Devic 症候群治疗计划
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 Devik 症候群治疗市场：依治疗方法

  • 皮质类固醇
  • 免疫抑制剂
  • 血浆置换术（血浆交换疗法）

第七章 Devik 症候群治疗市场：按分销管道

  • 诊所
  • 医院
  • 网路药房

第 8 章 Devik 症候群治疗市场：按最终用户分类

  • 成人
  • 儿科的

第九章 北美和南美Devik症候群治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区Devik症候群治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章 欧洲、中东和非洲Devik症候群治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准Ultomiris 用于治疗频谱谱系障碍，扩大了治疗范围
    • 加拿大卫生署核准UPLIZNA 用于治疗 NMOSD 成年患者
    • 中外製药针对 NMOSD 患者的 Enspring 在台湾上市
  • 战略分析和建议

公司名单

  • Accord Healthcare, Inc.
  • Alexion Pharmaceuticals, Inc by AstraZeneca PLC
  • Anant Pharmaceuticals Pvt. Ltd.
  • Apple Pharmaceuticals
  • Cadila Pharmaceuticals Limited
  • Chugai Pharma Taiwan Ltd.
  • Conscientia Industrial Co., Ltd
  • Evidentic GmbH
  • F. Hoffmann-La Roche Ltd
  • Healthy Life Pharma Pvt. Ltd.
  • Horizon Therapeutics plc by Amgen, Inc.
  • LEXICARE PHARMA PVT. LTD.
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Opexa Therapeutics, Inc.
  • Samsung Bioepis Co., Ltd. by Samsung Biologics
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC
Product Code: MRR-CB04E05660A7

The Devic's Syndrome Treatment Market was valued at USD 210.53 million in 2023, expected to reach USD 220.27 million in 2024, and is projected to grow at a CAGR of 4.68%, to USD 290.03 million by 2030.

Devic's Syndrome, also known as Neuromyelitis Optica Spectrum Disorder (NMOSD), is an autoimmune condition characterized by the inflammation and demyelination of the optic nerve and spinal cord. The scope for its treatment market is expanding due to increased awareness, rising prevalence, and advancements in medical technology enabling earlier diagnosis. The necessity for treatment arises from the chronic and relapsing nature of the disease, which can result in severe disability without intervention. The treatment approaches encompass plasma exchange, immunosuppressive therapies, and monoclonal antibodies like eculizumab, targeting the disease's underlying pathogenic mechanisms. End-use segments include hospitals, specialty clinics, and research institutes, with hospitals taking a significant share due to their comprehensive capabilities in managing acute cases.

KEY MARKET STATISTICS
Base Year [2023] USD 210.53 million
Estimated Year [2024] USD 220.27 million
Forecast Year [2030] USD 290.03 million
CAGR (%) 4.68%

Market growth is propelled by ongoing research and the introduction of novel therapeutics, while key drivers include a growing patient pool and increased healthcare spending. The rise in collaborative research initiatives further boosts innovation, with biotechnologies paving the way for more effective treatment options. However, the market faces challenges such as high treatment costs, a limited number of approved therapies, and regulatory hurdles which can stifle development pipelines. The potential opportunities lie in strategic partnerships, investing in personalized medicine, and exploring the untapped potential of emerging markets where awareness and diagnosis rates are low.

Nevertheless, limited awareness about NMOSD in developing regions and the complexity of clinical trials pose significant obstacles. For business growth, a promising area of innovation is the development of biomarkers for early detection, enhancing treatment efficacy, and patient outcomes. Insights into the market nature indicate a competitive landscape, primarily dominated by key pharmaceutical players with robust R&D capabilities and strategic alliances. Companies should focus on fostering collaboration across the healthcare ecosystem, optimizing supply chains, and increasing patient access through affordability programs to leverage these opportunities successfully.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Devic's Syndrome Treatment Market

The Devic's Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidences of Devic's Syndrome across the world
    • Efforts to raise awareness for neurological conditions and the emergence of advocacy groups
    • Favorable regulatory approvals and government initiatives to ensure access to Devic's syndrome treatments
  • Market Restraints
    • Complexity of the disease and the inability of treatments to tackle Devic's Syndrome
  • Market Opportunities
    • Ongoing initiatives to improve the efficacy and safety of Devic's Syndrome treatment solutions
    • Patient preference for personalized and specific treatment strategies
  • Market Challenges
    • Possibility of side effects of the treatment solutions for Devic's Syndrome

Porter's Five Forces: A Strategic Tool for Navigating the Devic's Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Devic's Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Devic's Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Devic's Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Devic's Syndrome Treatment Market

A detailed market share analysis in the Devic's Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Devic's Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Devic's Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Devic's Syndrome Treatment Market

A strategic analysis of the Devic's Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Devic's Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare, Inc., Alexion Pharmaceuticals, Inc by AstraZeneca PLC, Anant Pharmaceuticals Pvt. Ltd., Apple Pharmaceuticals, Cadila Pharmaceuticals Limited, Chugai Pharma Taiwan Ltd., Conscientia Industrial Co., Ltd, Evidentic GmbH, F. Hoffmann-La Roche Ltd, Healthy Life Pharma Pvt. Ltd., Horizon Therapeutics plc by Amgen, Inc., LEXICARE PHARMA PVT. LTD., Merck KGaA, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics, Inc., Samsung Bioepis Co., Ltd. by Samsung Biologics, Teva Pharmaceutical Industries Ltd., TG Therapeutics, Inc., Thermo Fisher Scientific Inc., and West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC.

Market Segmentation & Coverage

This research report categorizes the Devic's Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Corticosteroids, Immunosuppressants, and Plasma Exchange (Plasmapheresis).
  • Based on Distribution Channel, market is studied across Clinics, Hospitals, and Online Pharmacies.
  • Based on End User, market is studied across Adult Patients and Pediatric Patients.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of Devic's Syndrome across the world
      • 5.1.1.2. Efforts to raise awareness for neurological conditions and the emergence of advocacy groups
      • 5.1.1.3. Favorable regulatory approvals and government initiatives to ensure access to Devic's syndrome treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity of the disease and the inability of treatments to tackle Devic's Syndrome
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing initiatives to improve the efficacy and safety of Devic's Syndrome treatment solutions
      • 5.1.3.2. Patient preference for personalized and specific treatment strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Possibility of side effects of the treatment solutions for Devic's Syndrome
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Utilization of corticosteroids for Devic's Syndrome due to their effectiveness in rapidly controlling inflammation
    • 5.2.2. End User: Development of a comprehensive Devic's Syndrome treatment plans for adult patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Devic's Syndrome Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Corticosteroids
  • 6.3. Immunosuppressants
  • 6.4. Plasma Exchange (Plasmapheresis)

7. Devic's Syndrome Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Hospitals
  • 7.4. Online Pharmacies

8. Devic's Syndrome Treatment Market, by End User

  • 8.1. Introduction
  • 8.2. Adult Patients
  • 8.3. Pediatric Patients

9. Americas Devic's Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Devic's Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Devic's Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Approves Ultomiris for Neuromyelitis Optica Spectrum Disorder, Expanding Its Therapeutic Scope
    • 12.3.2. Health Canada Approves UPLIZNA for Adults with NMOSD
    • 12.3.3. Chugai Pharmaceutical's Enspryng Launches in Taiwan for NMOSD Patients
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accord Healthcare, Inc.
  • 2. Alexion Pharmaceuticals, Inc by AstraZeneca PLC
  • 3. Anant Pharmaceuticals Pvt. Ltd.
  • 4. Apple Pharmaceuticals
  • 5. Cadila Pharmaceuticals Limited
  • 6. Chugai Pharma Taiwan Ltd.
  • 7. Conscientia Industrial Co., Ltd
  • 8. Evidentic GmbH
  • 9. F. Hoffmann-La Roche Ltd
  • 10. Healthy Life Pharma Pvt. Ltd.
  • 11. Horizon Therapeutics plc by Amgen, Inc.
  • 12. LEXICARE PHARMA PVT. LTD.
  • 13. Merck KGaA
  • 14. Mitsubishi Tanabe Pharma Corporation
  • 15. Opexa Therapeutics, Inc.
  • 16. Samsung Bioepis Co., Ltd. by Samsung Biologics
  • 17. Teva Pharmaceutical Industries Ltd.
  • 18. TG Therapeutics, Inc.
  • 19. Thermo Fisher Scientific Inc.
  • 20. West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC

LIST OF FIGURES

  • FIGURE 1. DEVIC'S SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DEVIC'S SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DEVIC'S SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE (PLASMAPHERESIS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023